Clinical trial
PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
NCT00343954 · Angiogenix, Industry · Unknown status
Key facts
| NCT number | NCT00343954 |
|---|---|
| Title | PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease |
| Official title | Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease |
| Lead sponsor | Angiogenix, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Drug |
| Interventions | L-citrulline tablets, 1000 mg |
| Enrollment | 12 |
| First posted | Jun 23, 2006 |
| Last update posted | Jun 23, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: